Prelude Therapeutics
PRLD
60 hedge funds and large institutions have $188M invested in Prelude Therapeutics in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 24 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
31% more capital invested
Capital invested by funds: $144M → $188M (+$44.2M)
13% more funds holding
Funds holding: 53 → 60 (+7)
1.81% less ownership
Funds ownership: 87.35% → 85.54% (-1.8%)
46% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
+$549K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$511K |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$348K |
| 4 |
Citigroup
New York
|
+$330K |
| 5 |
6CM
683 Capital Management
New York
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$3.86M |
| 2 |
Morgan Stanley
New York
|
-$563K |
| 3 |
UBS AM
Chicago,
Illinois
|
-$427K |
| 4 |
BlackRock
New York
|
-$420K |
| 5 |
Two Sigma Investments
New York
|
-$344K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
51
Quantbot Technologies
New York
| $4.83K | -$3.85K | -600 | -43% |
|
52
Osaic Holdings
Scottsdale,
Arizona
| $3K | – | – | – |
|
|
CUAMC
53
China Universal Asset Management Company
Shanghai,
China
| $2.23K | -$500 | -78 | -17% |
|
54
Wells Fargo
San Francisco,
California
| $2.07K | -$186 | -29 | -8% |
|
55
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
56
Bessemer Group
Woodbridge,
New Jersey
| $1K | +$570 | +89 | New |
|
|
FIA
57
FNY Investment Advisers
New York
| $1K | +$1.28K | +200 | New |
|
58
Federated Hermes
Pittsburgh,
Pennsylvania
| $393 | -$8.6K | -1,342 | -95% |
|
|
HWM
59
HighMark Wealth Management
St. Paul,
Minnesota
| $302 | – | – | – |
|
60
Dimensional Fund Advisors
Austin,
Texas
| $77 | -$11.9K | -1,857 | -13% |
|
|
HA
61
HHLR Advisors
Grand Cayman,
Cayman Islands
| – | -$3.86M | -583,333 | Closed |
|
|
VEA
62
Virtus ETF Advisers
New York
| – | -$160K | -24,180 | Closed |
|
|
PP
63
PDT Partners
New York
| – | -$84K | -12,641 | Closed |
|
64
Simplex Trading
Chicago,
Illinois
| – | -$3K | -470 | Closed |
|
PRLD Hedge Fund Activity: Q4 2022 in Review
60 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2022, worth a combined $188M — up 31% from $144M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new PRLD positions and 5 closed out — a net gain of 7 holders — while 13 added to existing stakes and 24 trimmed.
The largest buyer was Barclays, adding an estimated $549K. The largest seller was HHLR Advisors, exiting entirely with an estimated $3.86M sold.
- 60 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2022, up from 53 in Q3 2022.
- Funds reported $188M of Prelude Therapeutics stock for Q4 2022, up 31% quarter-over-quarter.
- 12 funds opened new Prelude Therapeutics positions in Q4 2022 and 5 closed out, a net change of +7 holders.
- The largest Prelude Therapeutics buyer in Q4 2022 was Barclays, an estimated $549K added.
- The largest Prelude Therapeutics seller in Q4 2022 was HHLR Advisors, an estimated $3.86M sold.
Based on aggregated 13F filings for Q4 2022.